Aevi Genomic Medicine, Inc. (GNMX) financial statements (2021 and earlier)

Company profile

Business Address 435 DEVON PARK DRIVE,
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1234405333226
Cash and cash equivalents1234405333226
Prepaid expense and other current assets0
Other undisclosed current assets0101000
Total current assets:1235405434237
Noncurrent Assets
Property, plant and equipment0000000
Restricted cash and investments0000000
Other noncurrent assets 0    
Other undisclosed noncurrent assets    000
Total noncurrent assets:0000101
TOTAL ASSETS:1235415434238
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3353321
Accounts payable210 1  
Employee-related liabilities0122221
Other undisclosed accounts payable and accrued liabilities1131(0)00
Other undisclosed current liabilities2101111
Total current liabilities:4464432
Noncurrent Liabilities
Liabilities, other than long-term debt     12
Derivative instruments and hedges, liabilities     12
Other undisclosed noncurrent liabilities    101
Total noncurrent liabilities:    123
Total liabilities:4464556
Stockholders' equity
Stockholders' equity attributable to parent, including:831355030182
Common stock0000000
Additional paid in capital25424621518813010067
Accumulated deficit(246)(215)(180)(138)(100)  
Other undisclosed stockholders' equity attributable to parent     (82)(65)
Total stockholders' equity:831355030182
TOTAL LIABILITIES AND EQUITY:1235415434238

Income statement (P&L) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Operating expenses(9)(35)(42)(28)(19)(17)(13)
Other undisclosed operating income (loss)(22)  (8)(0)(0)0
Operating loss:(31)(35)(42)(37)(19)(18)(13)
Nonoperating income (expense)0(0)(0)(1)100
Investment income, nonoperating    000
Other nonoperating income (expense)0(0)(0)(1)1  
Loss from continuing operations before equity method investments, income taxes:(31)(35)(42)(38)(18)(18)(13)
Other undisclosed income (loss) from continuing operations before income taxes    (0)1(2)
Loss from continuing operations before income taxes:(31)(35)(42)(38)(18)(17)(15)
Income tax expense  (0)(0)(0)(0)(0)
Net loss attributable to parent:(31)(35)(42)(38)(18)(17)(15)
Other undisclosed net income available to common stockholders, basic  84763717 
Net income (loss) available to common stockholders, basic:(31)(35)4238180(15)
Dilutive securities, effect on basic earnings per share   11  
Net income (loss) available to common stockholders, diluted:(31)(35)4239190(15)

Comprehensive Income ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(31)(35)(42)(38)(18)(17)(15)
Comprehensive loss, net of tax, attributable to parent:(31)(35)(42)(38)(18)(17)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: